Trials / Terminated
TerminatedNCT00038922
Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Safety and Exploratory Pharmacogenomic Study of Orally Administered Recombinant Human Interleukin Eleven (rhIL-11) in Patients With Mild to Moderate Left-Sided Ulcerative Colitis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhIL-11 |
Timeline
- First posted
- 2002-06-07
- Last updated
- 2006-05-18
Source: ClinicalTrials.gov record NCT00038922. Inclusion in this directory is not an endorsement.